Vor Biopharma (VOR)
NASDAQ:VOR
Want to see VOR full AI Analyst Report?
VOR Stock Chart & Stats
$16.59
<$0.01(<0.01%)
At close: 4:00 PM EST
$16.59
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)1.22M
Market Cap
$685.33M
Enterprise Value-$297.33M
Total Cash (Recent Filing)$455.21M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)―
Beta4.59
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)82.04
Shares Outstanding48,847,504
10 Day Avg. Volume1,359,391
30 Day Avg. Volume1,218,320
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap-0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit350.62
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$36.00Price Target Upside117.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial Position And FundingA substantial cash position and low debt, supported by a private placement, can fund global Phase 3 programs and reduce near‑term financing pressure.
Market Access And AdoptionCommercial use with national reimbursement in China across multiple autoimmune indications indicates physician uptake and validates demand that supports broader commercial potential.
Mechanism Of ActionDual BAFF/APRIL inhibition targets multiple antibody classes and upstream B‑cell activity, offering a distinct mechanism that could provide clinical advantages versus single‑target therapies.
Bears Say
Clinical Translatability RiskEfficacy observed in China may not translate to broader global populations, creating uncertainty around the success of ongoing global Phase 3 studies.
Competitive LandscapeIntense competition in autoimmune therapies requires clear clinical and safety differentiation to capture market share, otherwise commercial uptake could be constrained.
Financing And Dilution RiskAdditional financing will likely be required to complete global development, introducing the risk of shareholder dilution and pressure on the stock.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $685.33M.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is May 07, 2026 which is in 7 days.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on Mar 30, 2026. The company reported $82.041 earnings per share for the quarter, beating the consensus estimate of $15.675 by $66.366.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 48,847,504 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of $82.041 in its last earnings report, beating expectations of $15.675. Following the earnings report the stock price went up 1.519%.
Which hedge fund is a major shareholder of Vor Biopharma?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.00 (117.00% Upside)
$36.00 (117.00% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.61%
12-Months-Change
Fundamentals
Return on Equity
72.70%
Trailing 12-Months
Asset Growth
203.89%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$36.00
▲(117.00% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
11.64% Insiders
5.28% Mutual Funds
0.19% Other Institutional Investors
77.41% Public Companies and
Individual Investors